Sandoz Group AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1986-01-01
- Employees
- 20K
- Market Cap
- $19B
- Website
- http://www.sandoz.com
Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit
Phase 3
Completed
- Conditions
- Neovascular Age-related Macular Degeneration (nAMD)
- Interventions
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2023-05-10
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 36
- Registration Number
- NCT05282004
- Locations
- 🇺🇸
Sandoz Investigational Site, Lynchburg, Virginia, United States
A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer
Phase 1
Completed
- Conditions
- Ovarian CancerBreast Cancer
- Interventions
- First Posted Date
- 2022-02-28
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 70
- Registration Number
- NCT05258747
- Locations
- 🇮🇳
Sandoz Investigative Site, Vijayawada, Andhra Pradesh, India
Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe
Phase 3
Completed
- Conditions
- Neovascular Age-related Macular Degeneration (nAMD)
- Interventions
- Drug: SOK583A1 (40 mg/mL)Device: Prefilled Syringe (PFS)
- First Posted Date
- 2021-12-17
- Last Posted Date
- 2022-11-18
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 30
- Registration Number
- NCT05161806
- Locations
- 🇺🇸
Sandoz Investigational Site, Liverpool, New York, United States
Efficacy and Safety of the Combination of Acetylcysteine, Paracetamol and Phenylephrine for the Treatment of Common Cold
Phase 3
Not yet recruiting
- Conditions
- Common Cold
- Interventions
- First Posted Date
- 2021-10-07
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 1002
- Registration Number
- NCT05070650
Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration
Phase 3
Completed
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Biological: Eylea EU (40 mg/mL)Biological: SOK583A1 (40 mg/mL)
- First Posted Date
- 2021-04-29
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 485
- Registration Number
- NCT04864834
- Locations
- 🇪🇸
Sandoz Investigational Site, Zaragoza, Spain
Study of LRG-002 Hard Capsules (Lek d.d., Slovenia) Used in the Prophylaxis of Antibiotic-associated Diarrhea in Adults.
- First Posted Date
- 2020-03-25
- Last Posted Date
- 2022-03-14
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 520
- Registration Number
- NCT04321460
- Locations
- 🇷🇺
Sandoz Investigative Site, Saint Petersburg, Russian Federation
An Open, Randomised, Single Dose, 2-period, 2-sequence Crossover Adhesion Study of Two Different Transdermal Patches Containing Rotigotine.
Phase 1
Terminated
- Conditions
- Parkinson Disease
- Interventions
- First Posted Date
- 2019-12-03
- Last Posted Date
- 2020-11-09
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 31
- Registration Number
- NCT04183634
- Locations
- 🇩🇪
Sandoz Investigative Site, Hamburg, Germany
Efficacy and Safety of Acetylcysteine for the Treatment of Acute Uncomplicated Rhinosinusitis
- First Posted Date
- 2019-10-10
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 944
- Registration Number
- NCT04123405
- Locations
- 🇷🇺
Sandoz Investigative Site, Yaroslavl, Russian Federation
This Was a Clinical Study Investigating the Moisturization and Desquamation Effect of AmLactin® Rapid Relief Restoring Lotion + Ceramides on Dry Skin in Healthy Female Volunteers. AmLactin® Rapid Relief is an Over-the-counter Cosmetic
Not Applicable
Completed
- Conditions
- Dry Skin
- Interventions
- Other: AmLactin® Rapid Relief
- First Posted Date
- 2019-09-11
- Last Posted Date
- 2023-05-10
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 56
- Registration Number
- NCT04085809
- Locations
- 🇺🇸
Sandoz Investigational Site, High Point, North Carolina, United States
Study to Test the Hypothesis of Non-inferior Efficacy and Safety of Ferrum Lek® (Iron (III) Hydroxide Polymaltosate), 100 mg Chewable Tablets (Lek d.d., Slovenia), as Compared With MALTOFER® (Vifor S.A., Switzerland), in Subjects With Mild and Moderate Iron Deficiency Anemia.
Phase 3
Completed
- Conditions
- Mild and Moderate Iron-deficiency Anaemia
- Interventions
- First Posted Date
- 2019-06-20
- Last Posted Date
- 2021-07-12
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 267
- Registration Number
- NCT03993288
- Locations
- 🇷🇺
Sandoz Investigative Site, Yaroslavl, Russian Federation
© Copyright 2025. All Rights Reserved by MedPath